Format

Send to

Choose Destination
Mol Ther Nucleic Acids. 2016 Apr 5;5:e303. doi: 10.1038/mtna.2016.14.

A Novel p19 Fusion Protein as a Delivery Agent for Short-interfering RNAs.

Author information

1
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, Ontario, Canada.
2
Department of Biology, University of Ottawa, Ottawa, Ontario, Canada.
3
Department of Chemistry and Biomolecular Sciences, University of Ottawa, Ottawa, Ontario, Canada.

Abstract

RNA interference (RNAi) is the biological mechanism that allows targeted gene knockdown through the addition of exogenous short-interfering RNAs (siRNAs) to cells and organisms. RNAi has revolutionized cell biology and holds enormous potential for human therapy. One of the major challenges facing RNAi as a therapy is achieving efficient and nontoxic delivery of siRNAs into the cell cytoplasm, since their highly anionic character precludes their passage across the cell membrane unaided. Herein, we report a novel fusion protein between the tombusviral p19 protein, which binds siRNAs with picomolar affinity, and the "TAT" peptide (RKKRRQRRRR), which is derived from the transactivator of transcription (TAT) protein of the human immunodeficiency virus and acts as a cell-penetrating peptide. We demonstrate that this fusion protein, 2x-p19-TAT, delivers siRNAs into the cytoplasm of human hepatoma cells where they elicit potent and sustained gene knockdown activity without toxic effects.

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center